Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$67.53 USD
+0.30 (0.45%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $67.54 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
EW 67.53 +0.30(0.45%)
Will EW be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EW
Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?
BD Stock Falls After Acquisition of Edwards' Critical Care Group
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
EW Stock Dips Following the Divestiture of Critical Care Wing
EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI
Why Is Waters (WAT) Down 2.2% Since Last Earnings Report?
Other News for EW
10 Health Care Stocks With Whale Alerts In Today's Session
Eyes on Fed ahead of expected interest rate cut: Morning Buzz
Edwards Lifesciences: Solvable Problems Offer Excellent Opportunities
Edwards Lifesciences downgraded at Jefferies on lower TAVR growth
Nvidia, ARM initiated: Wall Street's top analyst calls